Cytogenetic Risk Stratification of B-Acute Lymphoblastic Leukemia and Its Correlation with Other Prognostic Factors

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• B-Acute Lymphoblastic Leukemia (B-ALL) is a heterogeneous hematologic malignancy.
• Accurate risk stratification is crucial for optimizing treatment strategies in B-ALL.
• Cytogenetic abnormalities play a key role in determining B-ALL prognosis.

Purpose of the Study:

• To categorize WHO-defined B-ALL cases into cytogenetic risk groups (good, intermediate, poor).
• To assess the correlation of these cytogenetic risk groups with patient age and NCI risk criteria.
• To evaluate the association between cytogenetic risk groups and treatment response in B-ALL patients.

Main Methods:

• Analysis of clinical and diagnostic data from 78 newly diagnosed B-ALL patients.
• Utilized bone marrow morphology, flow cytometry, karyotyping, FISH, and RT-PCR.
• Categorized patients into cytogenetic risk groups and analyzed correlations with clinical parameters and treatment outcomes.

Main Results:

• Cytogenetic abnormalities were detected in 75.6% of cases.
• Significant associations were found between cytogenetic risk groups, age distribution (p<0.001), and NCI risk groups (p<0.001).
• Cytogenetic risk groups showed significant correlations with treatment response, including Day 8 steroid response (p=0.006), Day 15 bone marrow status (p=0.003), and measurable residual disease (MRD) on Day 33 (p=0.004) and Day 79 (p=0.012).

Conclusions:

• Cytogenetic risk stratification is a significant factor in B-ALL patient management.
• Cytogenetic risk groups are strongly associated with patient age and NCI risk criteria.
• These cytogenetic risk groups demonstrate a statistically significant correlation with treatment response, highlighting their importance in predicting outcomes.